Evidence map›Paper›PMID 37736725›Full record

ArticleBMC urology2023

Association of metabolic syndrome and its components with the risk of urologic cancers: a prospective cohort study.

Runxue Jiang, Xia Wang, Zhi Li, Haifeng Cai, Zhiguo Sun, Shouling Wu, Shuohua Chen, Hailong Hu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC urology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Urolithiasis in patients with cancer.Nature reviews. Urology · 2026
    Review
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Runxue Jiang *Department of Oncology Surgery, Tangshan People's Hospital, No.65 Shengli Road, Tangshan, 063000, China.
Xia Wang *Department of Gynaecology, Tangshan Hongci Hospital, Tangshan, 063000, China.
Zhi LiDepartment of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, No.23 Pingjiang Road, Tianjin, 300211, China.
Haifeng CaiDepartment of Oncology Surgery, Tangshan People's Hospital, No.65 Shengli Road, Tangshan, 063000, China.
Zhiguo SunDepartment of Oncology Surgery, Tangshan People's Hospital, No.65 Shengli Road, Tangshan, 063000, China.
Shouling WuHealth Department of Kailuan (Group), Tangshan, 063000, China.
Shuohua ChenHealth Department of Kailuan (Group), Tangshan, 063000, China.
Hailong HuDepartment of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, No.23 Pingjiang Road, Tianjin, 300211, China. tangshanwann@163.com.
Second Hospital of Tianjin Medical University · CNTangshan People's Hospital · CNKailuan General Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate the association between metabolic syndrome (MetS) and its components and the risk of developing urologic cancers.

methodsThis study included 101,510 observation subjects from May 2006 to December 2007. The subjects received questionnaires and were subjected to clinical and laboratory examinations to collect data on baseline population characteristics, waist circumference (WC), blood pressure (BP), blood glucose, blood lipids, lifestyle, and past disease history. Finally, follow-up was conducted from the date of recruitment to December 31, 2019. Cox proportional hazards modelling was applied to analyze the association between MetS and its components and the risk of developing urologic cancers.

resultsA total of 97,975 observation subjects met the inclusion criteria. The cumulative follow-up period included 1,209,178.65 person-years, and the median follow-up time was 13.03 years. During the follow-up period, 485 cases of urologic cancers (165 cases of kidney cancer, 134 cases of prostate cancer, 158 cases of bladder cancer, and 28 cases of other urologic cancers) were diagnosed. The log-rank test results for the cumulative incidences of urologic cancer, kidney cancer, and prostate cancer indicated significant (P < 0.01) differences between the MetS and non-MetS groups (0.70% vs. 0.48%, 0.27% vs. 0.15%, and 0.22% vs. 0.13%, respectively). Compared to the non-MetS group, the risk of developing urologic [HR (95% CI) = 1.29 (1.08-1.55)], kidney [HR (95% CI) = 1.74 (1.28-2.37)], and prostate [HR (95% CI) = 1.47 (1.04-2.07)] cancers was significantly higher in the MetS group. In the MetS group, elevated BP increased the risk of developing of urologic cancer [HRs (95% CI) = 1.35 (1.10-1.66)] and kidney cancer [HR (95% CI) = 1.74 (1.21-2.51)], while central obesity increased the risk of developing prostate cancer [HR (95% CI) = 1.68 (1.18-2.40)].

conclusionsMetS increased the risk of developing urologic, kidney, and prostate cancers but had no association with the development of bladder cancer.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsMetabolic SyndromeProstatic NeoplasmsUrinary Bladder NeoplasmsUrologic NeoplasmsHumansMaleProspective StudiesCohort studyMetabolic syndromeUrologic cancer

Identifiers

PMID37736725
PMCPMC10514929
OpenAlexW4386944997

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.